Last reviewed · How we verify
Pre-Pen (benzylpenicilloyl polylysine)
Benzylpenicilloyl polylysine (Pre-Pen), marketed by Allerquest, is a unique immunotherapy designed to reduce the risk of penicillin allergies. Its key strength lies in its mechanism of action, which stimulates the immune system to produce antibodies against penicillin, thereby providing a proactive solution to a common medical issue. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | benzylpenicilloyl polylysine |
|---|---|
| Sponsor | Allerquest |
| Drug class | benzylpenicilloyl polylysine |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1974 |
Approved indications
Common side effects
- Generalized erythema
- Urticaria
- Angioedema
- Dyspnea
- Hypotension
- Anaphylaxis
- Pruritus
- Local inflammatory response
Key clinical trials
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Evaluation of Skin Testing Reagents for Penicillin Allergy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pre-Pen CI brief — competitive landscape report
- Pre-Pen updates RSS · CI watch RSS
- Allerquest portfolio CI